TY - JOUR
T1 - Outcome prediction in primary resected retroperitoneal soft tissue sarcoma
T2 - Histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets
AU - Gronchi, Alessandro
AU - Miceli, Rosalba
AU - Shurell, Elizabeth
AU - Eilber, Fritz C.
AU - Eilber, Frederick R.
AU - Anaya, Daniel A.
AU - Kattan, Michael W.
AU - Honoré, Charles
AU - Lev, Dina C.
AU - Colombo, Chiara
AU - Bonvalot, Sylvie
AU - Mariani, Luigi
AU - Pollock, Raphael E.
N1 - Publisher Copyright:
© 2013 by American Society of Clinical Oncology.
PY - 2013/5/1
Y1 - 2013/5/1
N2 - Purpose: Integration of numerous prognostic variables not included in the conventional staging of retroperitoneal soft tissue sarcomas (RPS) is essential in providing effective treatment. The purpose of this study was to build a specific nomogram for predicting postoperative overall survival (OS) and disease-free survival (DFS) in patients with primary RPS. Patients and Methods: Data registered in three institutional prospective sarcoma databases were used. We included patients with primary localized RPS resected between 1999 and 2009. Univariate (Kaplan and Meier plots) and multivariate (Cox model) analyses were carried out. The a priori chosen prognostic covariates were age, tumor size, grade, histologic subtype, multifocality, quality of surgery, and radiation therapy. External validation was performed by applying the nomograms to the patients of an external cohort. The model’s discriminative ability was estimated by means of the bootstrap-corrected Harrell C statistic. Results: In all, 523 patients were identified at the three institutions (developing set). At a median follow-up of 45 months (interquartile range, 22 to 72 months), 171 deaths were recorded. Five- and 7-year OS rates were 56.8% (95% CI, 51.4% to 62.6%) and 46.7% (95% CI, 39.9% to 54.6%. Two hundred twenty-one patients had disease recurrence. Five- and 7-year DFS rates were 39.4% (95% CI, 34.5% to 45.0%) and 35.7% (95% CI, 30.3% to 42.1%). The validation set consisted of 135 patients who were identified at the fourth institution for external validation. The bootstrap-corrected Harrell C statistics for OS and DFS were 0.74 and 0.71 in the developing set and 0.68 and 0.69 in the validating set. Conclusion: These nomograms accurately predict OS and DFS. They should be used for patient counseling in clinical practice and stratification in clinical trials.
AB - Purpose: Integration of numerous prognostic variables not included in the conventional staging of retroperitoneal soft tissue sarcomas (RPS) is essential in providing effective treatment. The purpose of this study was to build a specific nomogram for predicting postoperative overall survival (OS) and disease-free survival (DFS) in patients with primary RPS. Patients and Methods: Data registered in three institutional prospective sarcoma databases were used. We included patients with primary localized RPS resected between 1999 and 2009. Univariate (Kaplan and Meier plots) and multivariate (Cox model) analyses were carried out. The a priori chosen prognostic covariates were age, tumor size, grade, histologic subtype, multifocality, quality of surgery, and radiation therapy. External validation was performed by applying the nomograms to the patients of an external cohort. The model’s discriminative ability was estimated by means of the bootstrap-corrected Harrell C statistic. Results: In all, 523 patients were identified at the three institutions (developing set). At a median follow-up of 45 months (interquartile range, 22 to 72 months), 171 deaths were recorded. Five- and 7-year OS rates were 56.8% (95% CI, 51.4% to 62.6%) and 46.7% (95% CI, 39.9% to 54.6%. Two hundred twenty-one patients had disease recurrence. Five- and 7-year DFS rates were 39.4% (95% CI, 34.5% to 45.0%) and 35.7% (95% CI, 30.3% to 42.1%). The validation set consisted of 135 patients who were identified at the fourth institution for external validation. The bootstrap-corrected Harrell C statistics for OS and DFS were 0.74 and 0.71 in the developing set and 0.68 and 0.69 in the validating set. Conclusion: These nomograms accurately predict OS and DFS. They should be used for patient counseling in clinical practice and stratification in clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=84884557274&partnerID=8YFLogxK
U2 - 10.1200/JCO.2012.44.3747
DO - 10.1200/JCO.2012.44.3747
M3 - Article
C2 - 23530096
AN - SCOPUS:84884557274
SN - 0732-183X
VL - 31
SP - 1649
EP - 1655
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 13
ER -